Skip to main content

The presence of bone marrow fibrosis is associated with poorer prognosis in newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.

Publication ,  Conference
Paul, B; Loitsch, G; Feinberg, D; Barak, I; Li, Z; Wang, E; Zhao, Y; Dupuis, M; Kang, Y
Published in: JOURNAL OF CLINICAL ONCOLOGY
May 20, 2019

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2019

Volume

37

Issue

15

Location

Chicago, IL

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Paul, B., Loitsch, G., Feinberg, D., Barak, I., Li, Z., Wang, E., … Kang, Y. (2019). The presence of bone marrow fibrosis is associated with poorer prognosis in newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 37). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
Paul, Barry, Gavin Loitsch, Daniel Feinberg, Ian Barak, Zhiguo Li, Endi Wang, Yue Zhao, Megan Dupuis, and Yubin Kang. “The presence of bone marrow fibrosis is associated with poorer prognosis in newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 37. AMER SOC CLINICAL ONCOLOGY, 2019.
Paul B, Loitsch G, Feinberg D, Barak I, Li Z, Wang E, et al. The presence of bone marrow fibrosis is associated with poorer prognosis in newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2019.
Paul B, Loitsch G, Feinberg D, Barak I, Li Z, Wang E, Zhao Y, Dupuis M, Kang Y. The presence of bone marrow fibrosis is associated with poorer prognosis in newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2019.

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2019

Volume

37

Issue

15

Location

Chicago, IL

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences